Pharma & Biotech
BioNTech Faces a Summer of Reckoning as Vaccine Revenues Wane and Oncology Data Takes Center Stage
BioNTech enters a critical stretch with no single event to anchor investor sentiment. The German biotech’s stock closed at €80.20...
Sellas Life Sciences Holds Its Breath as a Leukemia Trial Nears the Finish Line
The stock of Sellas Life Sciences has become a high-wire act, driven by a single, narrowing countdown: just two more...
Valneva’s Binary Outlook: A Broken Commercial Business Versus a Potentially Blockbuster Pipeline
For investors in Valneva, the gap between hope and reality has rarely been wider. The French biotech’s stock ended last...
Ocugen’s 673% Analyst Upside Hinges on a Tight Window of Clinical Data and Regulatory Submissions
A €10 price target with the stock trading at €1.29. That 673% gap isn't a typo — it's the distance...
Novo Nordisk Tests Resistance Near Overbought as Buyback and Oral Wegovy Drive Sentiment
Novo Nordisk closed the week at €43.32, adding 1.29% on Friday alone, as a wave of analyst upgrades and a...
Novo Nordisk Deploys Tiered Pricing and Weekly Insulin to Broaden GLP-1 Reach as Medicare Uptake Lags
Medicare Part D prescriptions for Wegovy surged nearly 600 percent within six months of the FDA’s March 2024 cardiovascular risk...
Ocugen’s Modifier Gene Therapy Targets Dozens of Blindness-Causing Mutations with One Drug
A single drug that could treat inherited blindness regardless of which gene is broken — that is the audacious promise...
Low-Volume Rally Drives Outlook Therapeutics 127% Higher Ahead of FDA Verdict
Outlook Therapeutics shares have more than doubled – and then some – over the past month, but the price action...
Bayer’s Ruveon Overhaul and Analyst Divergence Signal a Pivotal Moment After a 40% Rally
Bayer has moved decisively to reshape its US glyphosate operations, folding the business into a newly created entity called Ruveon...
BioNTech’s Oncology Ambition Faces a Trio of Tests: Clinical Data, Founder Departure, and Deep Cost-Cutting
BioNTech is entering a period where scientific validation, financial discipline, and leadership transition all converge. The stock closed Tuesday at...
Popular News
-
SunHydrogen Set for European Debut with Groundbreaking Technology
-
Walgreens Implements Deep Restructuring Following Private Buyout
-
Exploring the Rise of AI in Empowering Business and Personal Growth: Trends and Innovations
-
Trade Desk Shares Face Mounting Pressure as Tariff Warnings Materialize
-
Kraft Heinz Stock: A Contradiction in Market Sentiment
